Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 24;13(1):58.
doi: 10.1186/s13045-020-00881-7.

Emerging therapeutic agents for advanced non-small cell lung cancer

Ruqin Chen  1 , Rami Manochakian  1 , Lauren James  1 , Abdel-Ghani Azzouqa  1 , Huashan Shi  1 , Yan Zhang  1 , Yujie Zhao  1 , Kexun Zhou  1 , Yanyan Lou  2
Affiliations
Review

Emerging therapeutic agents for advanced non-small cell lung cancer

Ruqin Chen et al. J Hematol Oncol. .

Abstract

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanced NSCLC. In the last 10 years, the US Food and Drug Administration (FDA) has approved more than 17 new medications for this devastating disease and more are coming. Molecular and immunogenic testing makes personalized medicine possible for patients with advanced NSCLC. The new medications provide promising efficacy and safety resulting in improved long-term survival for a significant number of patients. In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to current standard drugs in the same class or are a completely new class of drugs with novel mechanisms of action. Advances are divided into (1) targeted agents, (2) antibody-drug conjugates, and (3) immunotherapies. Finally, we present a brief review of the emerging agents and ongoing clinical studies.

Keywords: Advanced non-small cell lung cancer; Clinical trials; Emerging therapeutic agents; Immunotherapy; NSCLC; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Mutation frequency of lung adenocarcinoma and emerging drugs targeted these mutations. Frequency data is a combination from the AACR GENIE data and Lung Cancer Mutation Consortium [73, 74]
See this image and copyright information in PMC

References

    1. Siegel Rebecca L., Miller Kimberly D., Jemal Ahmedin. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70(1):7–30. - PubMed
    1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899–909. - PMC - PubMed
    1. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172(5):523–529. - PubMed
    1. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–1440. - PubMed
    1. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–255. - PubMed

Publication types

MeSH terms